Company: CDLX
Filing Date: 2025-03-12
Form Type: 10-K
Source: 0001666071-25-000034
Chunk: 125

Company: Cardlytics, Inc.
Filing Date: 2025-03-12
Form: 10-K
Item: Item 8
Chunk 125
---
(134,702)(134,702)Balance – December 31, 202339,728 $9 $1,243,594 $2,467 $(1,111,272)$134,798 

See notes to the consolidated financial statements67

CARDLYTICS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Amounts in thousands)

Year Ended December 31, 2022:

  AdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncome (loss)AccumulatedDeficitTotal Common Stock SharesAmountBalance – December 31, 202133,534 $9 $1,212,823 $486 $(522,618)$690,700 Cumulative effect upon adoption of ASU— — (51,417)— 11,312 (40,105)Exercise of common stock options23 — 418 — — 418 Stock-based compensation— — 46,810 — — 46,810 Issuance of restricted stock986 — — — — — Common stock to be issued for the acquisition of Entertainment173 — 11,937 — — 11,937 Issuance of common stock under the ESPP167 — 1,997 — — 1,997 Repurchase and cancellation of common stock(1,406)— (40,000)— — (40,000)Other comprehensive loss— — — 5,112 — 5,112 Net loss— — — — (465,264)(465,264)Balance – December 31, 202233,477 $9 $1,182,568 $5,598 $(976,570)$211,605 

See notes to the consolidated financial statements68

CARDLYTICS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

 Year Ended December 31, 202420232022Operating activities Net Loss$(189,304)$(134,702)$(465,264)Adjustments to reconcile net loss to net cash (used in) provided by operating activities:Credit loss expense6,106 1,704 2,399 Depreciation and amortization25,689 26,460 37,544 Amortization of